Estrogen receptors alpha (rs2234693 and rs9340799), and beta (rs4986938 and rs1256049) genes polymorphism in prostate cancer: Evidence for association with risk and histopathological tumor characteristics in Iranian men

2012 ◽  
Vol 51 (S1) ◽  
pp. E104-E117 ◽  
Author(s):  
Mohammad Reza Safarinejad ◽  
Saba Safarinejad ◽  
Nayyer Shafiei ◽  
Shiva Safarinejad
Keyword(s):  
Prostate Cancer ◽  
Estrogen Receptors ◽  
Tumor Characteristics

Hypoxia and Inflammation in Prostate Cancer Progression. Cross-talk with Androgen and Estrogen Receptors and Cancer Stem Cells

2017 ◽  
Vol 16 (4) ◽  
pp. 235-248 ◽  
Author(s):  
Matteo Russo ◽  
Linda Ravenna ◽  
Laura Pellegrini ◽  
Elisa Petrangeli ◽  
Luisa Salvatori ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Stem Cells ◽  
Cancer Stem Cells ◽  
Estrogen Receptors ◽  
Cancer Progression ◽  
Cross Talk ◽  
Prostate Cancer Progression

Intratibial implantation of tumor cells  v1

2021 ◽  
Author(s):  
Shubhangi Agarwal ◽  
donna.peehl not provided ◽  
Renuka Sriram
Keyword(s):  
Prostate Cancer ◽  
Cancer Patient ◽  
Metastatic Prostate Cancer ◽  
Prostate Cancer Patient ◽  
Tumor Cell Line ◽  
Small Cell ◽  
Response To Therapy ◽  
Tumor Characteristics ◽  
Patient Derived Xenograft ◽  
Neuroendocrine Prostate Cancer

This protocol describes the steps required for the successful implantation of small cell neuroendocrine prostate cancer patient-derived xenograft (PDX) cells in the bone. Bone is one of the most common sites for the development of metastatic prostate cancer and its study is important for evaluating the tumor characteristics and response to therapy. This protocol can be used for the implantation of any tumor cell line in the bone.

scholarly journals Association of Statin Use With Pathological Tumor Characteristics and Prostate Cancer Recurrence After Surgery

2011 ◽  
Vol 185 (4) ◽  
pp. 1268-1273 ◽  
Author(s):  
Alison M. Mondul ◽  
Misop Han ◽  
Elizabeth B. Humphreys ◽  
Cari L. Meinhold ◽  
Patrick C. Walsh ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Recurrence ◽  
Tumor Characteristics ◽  
Prostate Cancer Recurrence ◽  
Statin Use

Effect of the simultaneous blockade of androgen and estrogen receptors on prostate cancer: Preliminary results.

2011 ◽  
Vol 29 (7_suppl) ◽  
pp. 168-168 ◽  
Author(s):  
R. Nunez-Nateras ◽  
E. P. Castle
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Synergistic Effect ◽  
Estrogen Receptors ◽  
Cell Lines ◽  
Simultaneous Administration ◽  
Normal Prostate ◽  
Androgen Receptor Antagonist ◽  
Receptor Modulator ◽  
Drug Concentrations

168 Background: Androgens and estrogens have been shown to play an important role in normal prostate development and function as well as carcinogenesis and development of the castration resistant phenotype of disease. The aim of this study was to evaluate the effect of a simultaneous administration of an androgen receptor antagonist (bicalutamide) and a selective estrogen receptor modulator (raloxifene) on both androgen sensitive and androgen insensitive prostate cancer cell lines. Methods: Experiments were performed on LNCaP, PC3 and DU145 cell lines. Western blot was utilized for the identification of androgen and estrogen receptors (a andb) in the cell lines. Drug concentrations required to achieve IC 50 were obtained using the MTT assay; such concentrations were identified for the drugs individually and when used in combination. The effect of the drugs on apoptosis was assessed using flow cytometry. Results: Results of the IC 50 for the drugs alone and in combination by each cell line are shown in the table. An enhanced effect was observed when the drugs were used in combination in all the cell lines. It was evident that the combination of the drugs decreased the total drug required to achieve the IC50 decreases considerably. Apoptosis rates were also affected by the simultaneous administration of bicalutamide and raloxifene. The synergistic effect of the combination was reflected in the increase of the apoptosis rate in all cell lines. Conclusions: The simultaneous administration of bicalutamide and raloxifene has a synergistic effect on cell death and apoptosis of DU145, PC3 and LNCaP cell lines. The pathway(s) responsible for this observation may be independent of the androgen receptor as both AR negative cell lines were still affected by the combination over the SERM alone. [Table: see text] No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document